Virtus ETF Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

Virtus ETF Advisers’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,784	Closed	-$174K	–	457
2022 Q1	$174K	Sell	11,784 -698	-6%	-$10K	0.08%	209
2021 Q4	$165K	Buy	12,482 +4,988	+67%	+$79.4K	0.06%	309
2021 Q3	$131K	Sell	7,494 -399	-5%	-$8.09K	0.06%	362
2021 Q2	$189K	Buy	+7,893	New	+$207K	0.08%	371
2019 Q4	–	Sell	-12,688	Closed	-$147K	–	483
2019 Q3	$147K	Sell	12,688 -707	-5%	-$11.4K	0.03%	277
2019 Q2	$297K	Buy	+13,395	New	+$314K	0.06%	219

Other funds holding KALV

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Virtus ETF Advisers's KALV Position: Q2 2022 in Review

Virtus ETF Advisers sold out of KalVista Pharmaceuticals (KALV) in Q2 2022, closing a stake of 11,784 shares — an estimated $174K sold.

Virtus ETF Advisers first reported a position in KALV in Q2 2019 and held it in 6 quarters. The position peaked at $297K in Q2 2019. 91 funds tracked by Wall St. Rank hold KALV as of Q2 2022.

Virtus ETF Advisers reported no remaining KalVista Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 11,784 KalVista Pharmaceuticals shares in Q2 2022, an estimated $174K.
Virtus ETF Advisers first reported a position in KalVista Pharmaceuticals in Q2 2019 and held it in 6 quarters.
Virtus ETF Advisers's KalVista Pharmaceuticals position peaked at $297K in Q2 2019.
91 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.